SPECTAZOLE
LOE ApproachingNDATOPICALCREAM
Approved
Dec 1982
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SPECTAZOLE is a topical cream small-molecule antifungal approved in 1982 for dermatological fungal infections. The exact mechanism of action and indications are not publicly detailed in available data, but topical antifungals typically work by disrupting fungal cell membrane integrity. It is used for localized fungal skin conditions requiring topical administration.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30/100), signaling a consolidating team focused on lifecycle management rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
SPECTAZOLE offers limited career growth potential given its LOE-approaching status and zero linked job openings. Roles on this product are primarily focused on lifecycle management, cost optimization, and defending market share against generics rather than driving innovation or expansion.
Brand ManagerProduct Manager
Worked on SPECTAZOLE at Alvogen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.